Regeneron Pharmaceuticals Inc $ 562.54 -11.07 (-1.93%)
Volume:
1,220,779
Avg Vol (1m):
687,153
Market Cap $:
60.01 Bil
Enterprise Value $:
59.08 Bil
P/E (TTM):
21.84
P/B:
6.59
Financial Strength | 8/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 1.42 | ||
| Equity-to-Asset | 0.63 | ||
| Debt-to-Equity | 0.25 | ||
| Debt-to-EBITDA | 0.63 | ||
| Interest Coverage | 91.44 | ||
| Piotroski F-Score | 5 | ||
| Altman Z-Score | 9.33 | ||
| Beneish M-Score | -2.9 | ||
| WACC vs ROIC | |||
Profitability Rank | 8/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | 34.64 | ||
| Net Margin % | 37.3 | ||
| ROE % | 28.39 | ||
| ROA % | 20.69 | ||
| ROC (Joel Greenblatt) % | 63.76 | ||
| 3-Year Revenue Growth Rate | 18 | ||
| 3-Year EBITDA Growth Rate | 23.4 | ||
| 3-Year EPS without NRI Growth Rate | 33.8 |
REGN
Valuation Rank | 7/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PE Ratio | 21.84 | ||
| Forward PE Ratio | 17.38 | ||
| PE Ratio without NRI | 21.84 | ||
| Price-to-Owner-Earnings | 26.79 | ||
| PB Ratio | 6.59 | ||
| PS Ratio | 8.13 | ||
| Price-to-Free-Cash-Flow | 26.9 | ||
| Price-to-Operating-Cash-Flow | 21.83 | ||
| EV-to-EBIT | 18.04 | ||
| EV-to-EBITDA | 16.88 | ||
| EV-to-Revenue | 7.38 | ||
| PEG Ratio | 0.83 | ||
| Shiller PE Ratio | 62.37 | ||
| Current Ratio | 2.12 | ||
| Quick Ratio | 1.68 | ||
| Days Inventory | 557.1 | ||
| Days Sales Outstanding | 108.62 | ||
| Days Payable | 147.08 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.3 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 6.6 | ||
| Price-to-Intrinsic-Value-Projected-FCF | 2.46 | ||
| Price-to-Median-PS-Value | 0.78 | ||
| Price-to-Peter-Lynch-Fair-Value | 0.93 | ||
| Price-to-Graham-Number | 2.53 | ||
| Earnings Yield (Greenblatt) % | 5.54 | ||
| Forward Rate of Return (Yacktman) % | 22.31 |